Business
Gelesis & Vedanta Data at Digestive Disease Week
Gelesis & Vedanta Data at Digestive Disease Week.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \nRNS Number : 8919Y PureTech Health PLC 14 May 2019 \n\n14 May 2019\n \nPureTech Health plc\n \nPureTech Health Affiliates Gelesis and Vedanta Biosciences Announce Presentations at Digestive Disease Week\n \nGelesis presents first clinical data for GS500 prototype for chronic idiopathic constipation\n \nVedanta presents expanded Phase 1a/1b study data of lead candidate, VE303, for recurrent Clostridium difficile infection\n \nBOSTON, May 14, 2019-PureTech Health plc (LSE: PRTC) (\"PureTech Health\"), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced that its affiliates Gelesis and Vedanta Biosciences will deliver poster presentations of clinical data at Digestive Disease Week, the world's largest gathering of physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.\n \nGelesis will present clinical data from a study of CSP01 (a prototype of the investigational hydrogel candidate GS500, in development for chronic idiopathic constipation (CIC)), which demonstrated that CSP01 provided a statistically significant reduction in colonic transit time in patients with CIC relative to placebo. \n \nVedanta Biosciences will present expanded, longer-term data from its successfully completed Phase 1a/1b study of VE303, the company's lead, orally-administered live biotherapeutic product candidate for recurrent Clostridium difficile infection.\n \nDetails of the presentations are as follows:\n \nGelesis\nSession Date and Time: May 19, 2019 from 12:00 PM to 2:00 PM\nSession Title: Constipation and Other Functional Colonic Syndromes\nPresentation Title: CSP01, A Novel Superabsorbent Hydrogel, Reduces Colonic Transit Time In Chronic Idiopathic Constipation: Results From A Pilot Randomized, Double-Blind, Placebo-Controlled Trial\nPoster Number: Su1638\n \nVedanta Biosciences\nSession Date and Time: May 20, 2019 from 12:00 PM to 2:00 PM \nPresentation Title: VE303, A Live Biotherapeutic Product For Prevention of Recurrent Clostridioides Difficile (C. Difficile) Infection. Preliminary Results Of A Phase 1, Open-Label Healthy Volunteers Study Of Oral VE303 After Vancomycin \nPoster Number: Mo1955\n \nAbout ...